Skip to main content

Duodenal Ulcer

4
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Livzon Pharmaceutical
Livzon PharmaceuticalChina - Zhuhai
3 programs
1
1
1
10 mg ilaprazolePhase 3Small Molecule1 trial
5 mg ilaprazolePhase 2/3Small Molecule1 trial
5 mg ilaprazolePhase 2Small Molecule1 trial
Active Trials
NCT00953381Completed235Est. May 2005
NCT02847455Completed408
NCT00952978Completed496Est. May 2006
Shandong Luoxin Pharmaceutical
1 program
1
LXI-15028 50mg groupPhase 31 trial
Active Trials
NCT05010954Completed400Est. Sep 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Helicobacter Pylori Eradication Treatment in Patients With Duodenal UlcersN/A1 trial
Active Trials
NCT01199536Completed59Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Shandong Luoxin PharmaceuticalLXI-15028 50mg group
Livzon Pharmaceutical10 mg ilaprazole
Livzon Pharmaceutical5 mg ilaprazole
Livzon Pharmaceutical5 mg ilaprazole
AstraZenecaHelicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers

Clinical Trials (5)

Total enrollment: 1,598 patients across 5 trials

NCT05010954Shandong Luoxin PharmaceuticalLXI-15028 50mg group

Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer

Start: Oct 2021Est. completion: Sep 2022400 patients
Phase 3Completed
NCT00952978Livzon Pharmaceutical10 mg ilaprazole

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)

Start: Sep 2005Est. completion: May 2006496 patients
Phase 3Completed
NCT02847455Livzon Pharmaceutical5 mg ilaprazole

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

Start: Aug 2008408 patients
Phase 2/3Completed
NCT00953381Livzon Pharmaceutical5 mg ilaprazole

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Start: Oct 2004Est. completion: May 2005235 patients
Phase 2Completed
NCT01199536AstraZenecaHelicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers

Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers

Start: Nov 2010Est. completion: Nov 201359 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.